Related Experiment Video
Updated: Jul 5, 2026
06:21
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma
Kimberly A Kelly1, Nabeel Bardeesy, Rajesh Anbazhagan
1Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, United States of America. kkelly9@partners.org
Plos Medicine
|April 18, 2008
Summary
Researchers identified plectin-1 as a novel biomarker for pancreatic ductal adenocarcinoma (PDAC). Targeted nanoparticles enabled early detection of PDAC lesions in mice, offering potential for improved diagnosis and treatment.
Area of Science:
- Oncology
- Biomarker Discovery
- Medical Imaging
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and resistance to therapy.
- Early detection and targeted therapies are crucial for improving PDAC outcomes.
- Novel molecular markers and imaging probes are needed for incipient PDAC.
Purpose of the Study:
- To identify novel molecular markers for PDAC.
- To develop targeted imaging agents for early PDAC detection.
- To validate plectin-1 as a PDAC biomarker and assess imaging probe utility.
Main Methods:
- Phage display screening in a mouse model of PDAC.
- Proteomics analysis to identify cell surface antigens.
- Conjugation of plectin-1 targeted peptides (PTP) to nanoparticles for imaging.
Main Results:
- Identified a motif distinguishing PDAC cells, leading to plectin-1 as a novel PDAC biomarker.
- Developed magnetofluorescent nanoparticles targeted to plectin-1.
- Enabled detection of small PDAC and precursor lesions using intravital microscopy and MRI.
Conclusions:
- Rapid identification and validation of PTP using a defined PDAC model.
- Plectin-1 is a novel biomarker for PDAC.
- The developed imaging probe and biomarker discovery hold potential for clinical diagnosis and management of PDAC.
